Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Pharma Officials Air Hopes and Concerns for New LDP Leader, Eyes on MHLW Revamp
Fumio Kishida is now set to become Japan’s next prime minister after clinching a victory in the ruling Liberal Democratic Party’s (LDP) presidential race on September 29. Some pharma officials have voiced expectations for his abilities to listen carefully to…
To read the full story
Related Article
- New Digital, Administrative Reform Minister Set to Break Silos, Propel Healthcare Revamp
October 6, 2021
- Economic Security Chief Vows to Beef Up Vaccine Development, Manufacturing in Japan
October 6, 2021
- Master Plan on COVID-19 Measures to Be Compiled Relatively Soon: Response Minister
October 6, 2021
- New Vaccine Czar Hints Booster Program Could Start in December
October 6, 2021
- Transparency and Predictability Up for Discussion towards 2022 Drug Pricing Reform: New Minister
October 6, 2021
- PM Kishida Orders 3 Ministers to Map Out Overall COVID-19 Response Plan
October 5, 2021
- New Health Minister Goto Vows to Protect Secure Healthcare System in FY2022 Reform
October 5, 2021
- All 4 Contenders in LDP Leadership Race Vow to Expand COVID-19 Measures
September 21, 2021
REGULATORY
- MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
- LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
- Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
May 27, 2026
- Ex-Minister Kato Preparing Parliamentary Group on Diabetes Issues
May 27, 2026
- LDP Lawmakers’ League Urges Economic Efficiency in Drug Use
May 27, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…